Cancer risk, metabolic dysfunction‐associated steatotic liver disease and metabolic dysfunction‐associated fatty liver disease: perspectives and methodological issues

Yasser Fouad, Mohammed Eslam

Open source

DOI
10.1111/imj.70596
Published
2026-07-25
Container
Internal Medicine Journal
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/imj.70596,
  title = {Cancer risk, metabolic dysfunction‐associated steatotic liver disease and metabolic dysfunction‐associated fatty liver disease: perspectives and methodological issues},
  author = {Yasser Fouad and Mohammed Eslam},
  year = {2026},
  journal = {Internal Medicine Journal},
  doi = {10.1111/imj.70596},
  url = {https://doi.org/10.1111/imj.70596}
}

RIS

TY  - JOUR
TI  - Cancer risk, metabolic dysfunction‐associated steatotic liver disease and metabolic dysfunction‐associated fatty liver disease: perspectives and methodological issues
AU  - Yasser Fouad
AU  - Mohammed Eslam
PY  - 2026
JO  - Internal Medicine Journal
DO  - 10.1111/imj.70596
UR  - https://doi.org/10.1111/imj.70596
ER  - 

APA

Fouad, Y., & Eslam, M. (2026). Cancer risk, metabolic dysfunction‐associated steatotic liver disease and metabolic dysfunction‐associated fatty liver disease: perspectives and methodological issues. Internal Medicine Journal. https://doi.org/10.1111/imj.70596

Source records